Hepatitis C News and Research RSS Feed - Hepatitis C News and Research

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.

The hepatitis C virus is usually transmitted through contact with the blood of an infected individual and, most commonly, people catch it through sharing contaminated needles when injecting illegal drugs.

Hepatitis C infection is categorized into an acute and a chronic stage. The acute phase describes the first 6 months of infection when there are not necessarily any symptoms. Around one quarter of people manage to clear the infection during this stage before disease progresses to the chronic stage.

People who go on to develop chronic hepatitis C may develop jaundice which turns the skin and whites of the eyes yellow. This is caused by the build-up of a yellow-colored substance in the blood called bilirubin that would usually be broken down by the liver if it was healthy. Chronic infection may eventually cause fibrosis and scarring (cirrhosis) of the liver, liver cancer or end stage liver failure.

Hepatitis C can be treated with antiviral medications that that are designed to disrupt the multiplication of virus particles inside the body and prevent liver damage.
New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet. [More]
New study in recognition of World Hepatitis Day released on Life Sciences Connect

New study in recognition of World Hepatitis Day released on Life Sciences Connect

The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill. [More]
First Edition: July 28, 2014

First Edition: July 28, 2014

Today's headlines include reports about the deal reached by House and Senate negotiators regarding veterans' health care. [More]
Researchers provide global genotype prevalence estimates for HCV

Researchers provide global genotype prevalence estimates for HCV

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. [More]
Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated for patients infected with the genotype 1 virus. Telaprevir is available in Trinidad under the trade brand INCIVO®. [More]
Viewpoints: Ryan's 'thoughtful blueprint' to end poverty; GOP challenges after health law ruling

Viewpoints: Ryan's 'thoughtful blueprint' to end poverty; GOP challenges after health law ruling

The Republican chairman of the House Budget Committee today released a thoughtful blueprint for overhauling $800 billion worth of U.S. anti-poverty programs. [More]
RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities. [More]
MedMira adds three new rapid vertical flow tests to Multiplo product line

MedMira adds three new rapid vertical flow tests to Multiplo product line

MedMira, Inc. is expanding its Multiplo product line with the addition of three new multiplex tests that deliver instant, simultaneous, single-cartridge results for syphilis (TP), HIV, and hepatitis C. [More]

Expensive hepatitis drug challenges Medicaid programs' funding

State officials are nervous about how to afford the new medicine, which can run $84,000 for treatment. Also in Medicaid news, federal data show children using emergency room treatment at night or weekends are often on Medicaid. [More]
First Edition: July 25, 2014

First Edition: July 25, 2014

Today's headlines include reports that the Obama administration is moving ahead in preparations for the health law's employer mandate. [More]
$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, putting it on track to become one of the world's best-selling medicines and intensifying concerns about its costs. [More]
First Edition: July 24, 2014

First Edition: July 24, 2014

Today's headlines include more analysis of this week's conflicting appeals courts' decisions regarding a key part of the health law. [More]
New momentum: WHO welcomes progress in tackling viral hepatitis

New momentum: WHO welcomes progress in tackling viral hepatitis

On World Hepatitis Day, 28 July, WHO welcomes new progress in tackling one of the world's most serious diseases. Viral hepatitis - a group of infectious diseases known as hepatitis A, B, C, D, and E - affects millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year. [More]
Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’ [More]

Drug industry news: FDA again offers warning about a Dallas compounding pharmacy; more on Sovaldi

For the third time in 15 months, the FDA is warning health care providers and consumers not to use drugs that were made by a Dallas compounder because the medicines may be contaminated. And the ongoing struggle between the agency and NuVision Pharmacy underscores the difficulties that beset the pharmaceutical supply chain despite a recently passed law designed to bolster safety (Silverman, 7/21). [More]

Cost of Sovaldi and other specialty drugs worries states, pharmaceutical executives

News outlets continue to examine how Solvadi - usually an expensive cure for hepatitis-C - might affect budgets. [More]
First Edition: July, 21, 2014

First Edition: July, 21, 2014

Today's headlines include a story about an effort by regulators to widen insurer networks, as well as a range of other health policy developments. [More]
State highlights: Concerns continue about Coakley-partners antitrust settlement; Maine's Lepage announces extra $13.1 million for nursing homes

State highlights: Concerns continue about Coakley-partners antitrust settlement; Maine's Lepage announces extra $13.1 million for nursing homes

Criticism of Attorney General Martha Coakley's antitrust pact with the state's largest health care system mounted Thursday as a watchdog panel warned a judge the proposed deal might not meet its goal of holding down medical expenses. [More]

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C. [More]
UT Southwestern researcher named recipient of ASBMB Merck Award for research on molecular biology

UT Southwestern researcher named recipient of ASBMB Merck Award for research on molecular biology

Dr. Zhijian "James" Chen, Professor of Molecular Biology and a Howard Hughes Medical Institute investigator at UT Southwestern Medical Center, has been named the 2015 recipient of the American Society for Biochemistry and Molecular Biology Merck Award, which recognizes outstanding contributions to research in biochemistry and molecular biology. [More]